UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934
May 10, 2010
Date of Report (Date of earliest event reported)
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
| Nevada
|
|
001-13305
|
|
95-3872914 |
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification
Number) |
| |
|
|
|
|
311 Bonnie Circle
Corona, California
(Address of principal
executive offices)
|
|
|
|
92880
(Zip Code) |
(951) 493-5300
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On May 10, 2010, Watson Pharmaceuticals, Inc. (the “Company”) issued a press release reporting
the financial results of the Company for the first quarter ended March 31, 2010, and providing a
forecast of certain estimated financial metrics for 2010. A copy of the Company’s press release is
attached to this report as Exhibit 99.1 and incorporated herein by reference.
In its press release, the Company included non-GAAP financial measures, as defined in
Regulation G promulgated by the U. S. Securities and Exchange Commission. The Company believes
that its inclusion of non-GAAP financial measures provides useful supplementary information to and
facilitates analysis by investors in evaluating the Company’s performance and trends. The Company
uses both GAAP financial measures and the disclosed non-GAAP financial measures internally to
evaluate and manage the Company’s operations and to better understand its business. These non-GAAP
financial measures are in addition to, not a substitute for, or superior to, measures of financial
performance prepared in accordance with GAAP.
The information in this report (including the exhibit) is furnished pursuant to Item 2.02 and
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
d. Exhibits:
| |
|
|
|
99.1
|
|
Press Release titled “Watson Q1 Net Revenue Climbs 28 Percent to $857
Million” dated May 10, 2010. |
2